UCB opens new $40M Keppra facility
Begium-based UCB Pharma, a division of the drugs and chemicals firm UCB Group, says that HRH Prince Philippe of Belgium has inaugurated the firm's new manufacturing plant for its antiepileptic drug Keppra (levetiracetam) in Braine-l'Alleud.
The new production installation, which operates fully to Good Manufacturing Practice standards, has been set up in order to meet the steadily growing demand for the agent, and represents an investment of 30 million euros ($40 million) creating 120 new jobs, the company noted.
Production at the new facility, which applies a unique manufacturing technology known as continuous chiral chromatographic separation, is 150 tonnes per year, adding to the 80 tonnes/year made at the Bulle, Switzerland site.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze